Avalon GloboCare Corp

Avalon GloboCare Corp. is a holding company, which engages in the development of biotechnology and the provision of healthcare services. It operates through the following segments: Real Property Operating, Medical Related Consulting Services, and Development Services & Sales of Developed Products. It offers regenerative medicine, cell-based immunotherapy, exosome technology, and rehabilitation medicine through Avalon Cell and Avalon Rehab platforms. The company was founded on July 28, 2014 and is headquartered in Freehold, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Avalon GloboCare Corp. is a clinical-stage biotechnology company, which engages in the development of immune effector cell therapy and laboratory services. It operates through the Real Property Operating and Medical Related Consulting Services segments. The Real Property Operating segment includes property management fees, property insurance, real estate taxes, depreciation, repairs and maintenance fees, utilities and other expenses related to rental properties. The Medical Related Consulting segment relates to labor and related benefits, travel expenses, and related to consulting services. The company was founded on July 28, 2014 and is headquartered in Freehold, NJ.

FREEHOLD, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, today announced the launch of the "BrAce for Impact" affiliate marketing program for KetoAir™, a handheld breathalyzer device equipped with AI-enabled software and Hot App shareable technology, specifically designed for ketogenic health monitoring.

Avalon GloboCare Launches “BrAce for Impact" Affiliate Marketing Program for the KetoAir Breathalyzer Device

FREEHOLD, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, today announced that it entered into a memorandum of understanding (the “MOU”) with Qi Diagnostics Limited (“Qi Diagnostics”), a nanosensor-based diagnostic technologies company, to explore a proposed strategic collaboration to co-develop a VOC (volatile organic compound) nanosensor-based point-of-care cannabis breathalyzer. The MOU provides Avalon with an exclusivity period of 120 days (the “Exclusivity Period”), during which Avalon intends to negotiate with Qi Diagnostics and enter into a definitive agreement regarding the proposed strategic collaboration.

Avalon GloboCare and Qi Diagnostics Enter into Memorandum of Understanding for Proposed Co-Development of Real-Time Cannabis Breathalyzer for Detecting Potential Impaired Driving

Avalon GloboCare (NASDAQ: ALBT ) stock is up on Wednesday alongside news of a new medical device being launched by Laboratory Services MSO. Laboratory Services MSO is preparing to launch its GeeWhiz External Condom Catheter in the third quarter of 2024.

Why Is Avalon GloboCare (ALBT) Stock Up 173% Today?

Direct-To-Consumer, Non-Invasive Kit is Available in the U.S. for Convenient At-Home Sample Collection Direct-To-Consumer, Non-Invasive Kit is Available in the U.S. for Convenient At-Home Sample Collection

Avalon's Laboratory Services MSO Launches DNA Testing Kit for Predisposition to Opioid Addiction

Avalon GloboCare Corp (NASDAQ:ALBT) said it had successfully launched its KetoAir breathalyzer in the US at the Hack Your Health by KetoCon 2024 Conference. Avalon CEO David Jin told shareholders that the booth at the event in Austin “attracted a diverse group of potential clients and partners, including doctors, disease management companies, health and keto coaches, consumers, keto product manufacturers, and service providers interested in establishing a marketplace on our app and device.

Avalon GloboCare unveils KetoAir breathalyzer at KetoCon 2024

Avalon Globocare (NASDAQ: ALBT ) stock is down on Tuesday but only after the commercial real estate company's shares underwent a massive rally on Monday on a recent filing. That rally came after the company filed its Form 10-Q with the Securities and Exchange Commission (SEC).

Why Is Avalon Globocare (ALBT) Stock Down 27% Today?

FREEHOLD, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that it received a notice (the “Notice”) on May 22, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) because the Company has not yet filed its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 (the “Quarterly Report”) with the Securities and Exchange Commission (the “SEC”).

Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report

Avalon GloboCare Corp (NASDAQ:ALBT) officially unveiled its KetoAir breathalyzer device in the United States at the Hack Your Health by KetoCon 2024 Conference. Specifically engineered for ketogenic health management, KetoAir utilizes nano-sensor-based technology and AI algorithms to not only assess the user's ketosis status but also seamlessly record diet and exercise details into an app.

Avalon GloboCare launches KetoAir breathalyzer in the US

FREEHOLD, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced the official launch of the KetoAir™ breathalyzer device and related accessories in the U.S. at the Hack Your Health by KetoCon 2024 Conference being held from May 31 to June 2, 2024 in Austin, Texas.

Avalon GloboCare Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference

Avalon GloboCare Corp (NASDAQ:ALBT) announced the extension of its exclusive distribution agreement with Qi Diagnostics for the KetoAir breathalyzer device and related accessories in several key regions, including North America, South America, the United Kingdom and the European Union.   Shares of the biotechnology company added 19% at US$0.36 before Thursday's opening bell on the news.

Avalon GloboCare extends exclusive distribution agreement for KetoAir breathalyzer

FREEHOLD, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, is pleased to announce the extension of its exclusive distribution agreement with Qi Diagnostics Limited (“Qi Diagnostics”) to distribute the KetoAir™, a breathalyzer device and related accessories, including current and future models, in key regions including North America, South America, the United Kingdom, and the European Union.

Avalon GloboCare Extends Exclusivity Agreement to Distribute KetoAir Breathalyzer Device and AI-Enabled Software in North America, South America, United Kingdom and European Union

Avalon GloboCare Corp (NASDAQ:ALBT) announced that it has engaged ChtrBx, a marketing and branding company, to develop a marketing launch plan for KetoAir in North America, South America, the United Kingdom (UK) and the European Union (EU).  The developer of innovative cell-based technology, cellular therapy and precision diagnostics said KetoAir functions as a companion diagnostic and monitoring device, combined with an artificial intelligence (AI) nutritionist consultation for ketogenic dietary management.

Avalon GloboCare engages ChtrBx to develop marketing launch plan for KetoAir

FREEHOLD, N.J., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced that it engaged ChtrBx, a marketing and branding company, to develop a marketing launch plan for KetoAir™ in North America, South America, the United Kingdom (UK) and the European Union (EU).

Avalon GloboCare Engages ChtrBx, a Marketing and Branding Company, to Launch KetoAir in the US

Avalon GloboCare Corp (NASDAQ:ALBT) shares rose in early trade after it announced a partnership with medical device company Qi Diagnostics to co-develop international multi-center clinical studies for the DKAir breathalyzer device for the early detection of diabetic ketoacidosis (DKA). Developed by Qi Diagnostics, the DKAir is a handheld breathalyzer that allows diabetic patients to detect the level of acetone in their breath.

Avalon GloboCare partners with Qi Diagnostics on clinical studies of DKAir breathalyzer for diabetic ketoacidosis

Avalon GloboCare Corp (NASDAQ:ALBT) has officially unveiled its KetoAir mobile application on the Apple App Store. Coupled with an AI nutritionist and a nanosensor-based breathalyzer, KetoAir serves as a companion diagnostic and monitoring device for individuals practicing a ketogenic lifestyle The app, designed to facilitate ketogenic dietary management, is now also available for download on the Google Play store.

Avalon GloboCare debuts KetoAir app on Apple App Store

KetoAir™ Mobile Application Launches in Apple App  Store KetoAir™ Mobile Application also Available in the Google Play Store FREEHOLD, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced the launch of the KetoAir™ mobile application in the Apple App store.

Apple Approves Use of Avalon GloboCare's KetoAir Mobile Application

Avalon GloboCare Corp (NASDAQ:ALBT) announced that its 40% owned clinical diagnostics and reference lab Laboratory Services MSO (LSM) has made two significant accretive acquisitions: Merlin Medical Supply (MMS) and Leading Edge Innovations.  MMS is a home medical equipment and durable medical equipment company operating in Ventura County, California, which has contracts with major healthcare payers, including Medicaid, Medicare, Medi-Cal, Optum-Rx, CCS, Tri-Care, Blue Cross/Blue Shield, Humana, Aetna, United Health and Gold Coast.

Avalon GloboCare shares spike on Laboratory Services MSO acquisitions

FREEHOLD, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC (“LSM”), has acquired Merlin Medical Supply (“MMS”), a profitable, well-established Home Medical Equipment (“HME”) and Durable Medical Equipment (“DME”) company providing acute and non-acute medical supplies in Ventura County, California. Additionally, LSM has acquired Leading Edge Innovations, LLC from the same owner. Leading Edge Innovations owns the GeeWhiz External Condom Catheter, a patented, FDA-registered, in-market, male incontinence device. Avalon owns a 40% interest in LSM.

Avalon's Laboratory Services MSO Acquires California-Based Medical Supply Company and Proprietary FDA-Registered External Male Catheter Device

Avalon GloboCare Corp (NASDAQ:ALBT) shares climbed 29% to $1.24 on Tuesday after the precision diagnostics and clinical laboratory services provider said it received a new US patent titled "QTY Fc Fusion Water Soluble Receptor Proteins," a collaborative effort with Dr Shuguang Zhang of the Massachusetts Institute of Technology (MIT), which encompasses the composition and methodology for a groundbreaking technology known as the "QTY Code."   According to the company, the QTY Code has the potential to transform water-insoluble transmembrane receptor proteins into their water-soluble counterparts, thereby expanding the horizon of therapeutic targets for conditions like cancer and diseases.

Avalon GloboCare shares surge as recent momentum continues

Avalon GloboCare Corp (NASDAQ:ALBT) has received a new patent to add to its portfolio. The Freehold, New Jersey-based company announced the United States Patent and Trademark Office (USPTO) issued a Notice of Publication for U.S.

Avalon GloboCare adds QTY Code patent to its portfolio

Avalon GloboCare Corp (NASDAQ:ALBT) announced that its 40% owned Laboratory Services MSO, LLC (LSM) is now offering an in-house laboratory developed test (LDT) to detect tuberculosis (TB) using a patient's sputum sample.  The developer of innovative cell-based technology, cellular therapy and precision diagnostics said the new test method is expected to generate revenue in 2023.

Avalon GloboCare investee LSM launches innovative lab test for tuberculosis

New Proprietary Testing Method Makes Tuberculosis Diagnosis Easier and Faster New Test Method Expected to Generate Revenue in 2023 FREEHOLD, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced that Laboratory Services MSO, LLC (“LSM”) is now offering an in-house laboratory developed test (“LDT”) to detect Tuberculosis (“TB”) using a patient's sputum sample.

Avalon's Laboratory Services MSO Launches Innovative Laboratory Test for Tuberculosis

Avalon GloboCare Corp (NASDAQ:ALBT) told investors that Laboratory Services MSO (LSM), in which it owns a 40% interest, is opening a new laboratory — Veritas Laboratories — in Scottsdale, Arizona.  The company noted that Veritas is a CLIA-certified and COLA-accredited laboratory that offers a wide range of high-quality testing, including drug testing, genetic testing, urinary testing and COVID-19 PCR testing.

Avalon GloboCare announces Laboratory Services MSO's expansion into Arizona

New Wholly Owned Lab “Veritas Laboratory” of Arizona, Anticipated to Generate Revenue in 2023 Engages Former Congressman Barry M. Goldwater Jr. To Expand Insurance Coverage and Grow Lab Footprint FREEHOLD, N.J.

Avalon's Laboratory Services MSO Announces Expansion into Arizona

Avalon GloboCare Corp (NASDAQ:ALBT) announced that Laboratory Services MSO, in which the company holds a 40% interest, has acquired DE Laboratory LLC.  The Houston-based lab expands LSM's market penetration in Texas and provides a wide range of high-quality testing, including drug testing, genetic testing, urinary testing and COVID-19 PCR testing, according to a statement.

News for Avalon GloboCare Corp Stock (ALBT)